Background The mean age of patients with chronic hepatitis C virus (HCV) infection in the USA has been increasing. Despite the increasing proportion of HCV-infected elderly patients, this group is under-represented in clinical trials of HCV treatment. Aim We aimed to describe the real-world effectiveness of direct-acting antivirals (DAAs) among elderly patients. Patients and methods We retrospectively identified 17 487 HCV-infected patients who were started on treatment with sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ombitasvir/ritonavir/dasabuvir-based regimens in the Veterans Affairs Healthcare System between 1 January 2014 and 30 June 2015. We ascertained sustained virologic response (SVR) rates in patients aged below 55, 55-59, 60-64, 65-69, 70-74, and 55, 55-59, 60-64, 65-69, 70-74, and 75 years or older. Unadjusted SVR rates were similar in all age groups after stratifying by genotype, treatment regimen, stage of liver disease, and treatment experience. In multivariate models, age was not predictive of SVR after adjusting for confounders. Conclusion DAAs produce high rates of SVR in all age groups, including patients in our oldest age category (≥75 years). Advanced age in and of itself should not be considered a barrier to initiating DAA treatment. Eur J Gastroenterol Hepatol 29:686-693
Introduction
Most individuals with chronic hepatitis C (HCV) infection in the USA were born between 1945 and 1965 and infected between 1970 and 1990 [1, 2] when the incidence of new HCV infections peaked at an estimated 380 000 per year [3] . Members of this 'baby-boomer' birth cohort are currently aged 50-70 years and have been infected for years. This birth cohort is driving an increase in the average age of HCV-infected patients in the USA [4] . They are also contributing to an increase in the prevalence of cirrhosis and the incidence of hepatocellular carcinoma (HCC) as patients move through the clinical phases of HCV-related liver disease [5] .
In anticipation of the aging of the HCV-infected population, it is imperative to understand how elderly patients respond to antiviral therapy as they will soon constitute the majority of patients receiving treatment. Interferon-based treatments were poorly tolerated in most patients, especially in the elderly, because of significant adverse effects. Furthermore, studies of the association between advanced age and likelihood of sustained virologic response (SVR) with interferon-based regimens yielded mixed results. Whereas some studies found that older patients had lower unadjusted SVRs compared with younger patients and more frequent treatment discontinuation or dose reductions [6, 7] , others found no difference [8, 9] . Studies that specifically assessed whether advanced age was an independent predictor of SVR also produced mixed results, with some studies demonstrating an association between age and failure to achieve SVR [6] and others showing that age was not predictive of SVR after adjusting for confounders [8] .
The introduction of sofosbuvir (SOF) in December 2013 and of ledipasvir/sofosbuvir (LDV/SOF) and paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD) in October and December 2014, respectively, made highly effective, well-tolerated, interferon-free antiviral regimens available for most patients. We previously reported that these regimens produce high rates of SVR in real-world practice in veterans with chronic HCV in the USA [10] . Here, we compare the rates of SVR in patients of different age groups treated with SOF-based, LDV/SOF-based, and PrOD-based regimens in the Veterans Affairs (VA) National Healthcare System.
Patients and methods
Data source, study population, and antiviral regimens Data were obtained from the VA Corporate Data Warehouse [11] . We identified 24 089 HCV antiviral regimens initiated between 1 January 2014 and 30 June 2015 and completed before 1 October 2015 at VA facilities nationally. We excluded 6193 regimens no longer recommended in the VA at the time of the study, such as SOF + simeprevir ribavirin (n = 3669), SOF + pegylated interferon RBV for genotype 1 HCV (n = 1766), SOF + RBV for genotype 1 HCV (418), or other regimens (n = 340). We excluded 409 duplicate regimens. This left 17 487 patients/regimens in our study. All regimens included SOF, LDV/SOF, or PrOD. Data collection was extended to 10 April 2016 to allow for completion of regimens and ascertainment of SVR.
Sustained virologic response
SVR was defined as a viral load below the lower limit of quantification at least 12 weeks after the end of treatment [12] . When SVR at 12 weeks or more was not available, SVR was defined by viral load testing between 4 and 12 weeks after treatment completion. SVR at 4 weeks was shown to have 98% concordance with SVR at 12 weeks (positive predictive value, 98%; negative predictive value, 100%) in SOF-treated patients [13] .
Baseline characteristics
Our data extended to 1 October1999 to ascertain baseline characteristics, which reflect information in medical records before the initiation of antiviral treatment. We extracted baseline characteristics listed in Table 1 based on ICD-9 codes previously validated in VA medical records [5, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] (Supplemental Table 1 , Supplemental digital content 1, http://links.lww.com/EJGH/A176). We identified relevant laboratory tests and recorded the value closest to the treatment starting date within the preceding 6 months. We also calculated the FIB-4 score [14] [FIB-4 = (age × aspartate transaminase)/(platelets × alanine transaminase 1/2 )], which correlates with hepatic fibrosis.
Statistical analysis
We assessed SVR rates by age group, genotype, treatment regimen, and clinical subgroups. Multivariable logistic regression models were used to evaluate the association between age and SVR, adjusting for potential confounders (sex, race/ethnicity, history of alcohol use disorders, HCV genotype and subgenotype, HCV regimen, baseline HCV viral load, diabetes, treatment naive/experienced, cirrhosis, decompensated cirrhosis, HCC, liver transplantation, platelet count, and serum bilirubin and albumin levels). A significant proportion of patients (9%, N = 1603) had missing SVR data. To evaluate the impact of missing SVR, we compared baseline characteristics of patients with and without SVR data to determine whether there were significant differences that could bias our results. We also compared treatment durations of patients with and without SVR data to determine whether patients missing SVR were more likely to have early treatment discontinuation and thus lower likelihood of achieving SVR. Finally, we used multiple imputation to calculate missing SVR values using a logistic regression model with baseline characteristics shown in Table 1 and duration of treatment. Analyses were performed using Stata/MP, version 14.1 (64-bit) (StataCorp, College Station, Texas, USA).
Results

Baseline characteristics
The mean age of the treatment recipients was 60.8 ( 6.5) years and the median age was 61 years. The age distribution was as follows: 10 The observed SVR rates among the 15 884 patients with available SVR data are shown in Table 2 and Fig. 1 . Overall rates of SVR were similar across age bands, including patients younger than 55 (91.2%) years, between 55 and 59 (89.8%) years, 60 and 64 (90.8%) years, 65 and 69 (91.1%) years, 70 and 74 (90.0%) years, and 75 (93.8%) years or older ( Fig. 1a and Table 2 ). There were no consistent age-related trends after stratifying by genotype and treatment regimen ( Fig. 1b and Table 2 ).
Association between age and sustained virologic response within subgroups defined by cirrhosis or receipt of prior treatment
Among noncirrhotic patients, SVR rates were more than 90% in all age groups with minimal variability between groups ( Fig. 1c and Table 2 ). Compared with noncirrhotic individuals, patients with cirrhosis or with decompensated cirrhosis generally had lower SVRs but SVRs were similar between age groups ( Fig. 1c and Table 2 ). HCV treatmentnaive patients had slightly higher rates of SVR than treatment-experienced patients, with no major differences in SVRs between age groups ( Fig. 1d and Table 2 ).
Association between age and sustained virologic response in multivariable models
We used multivariable logistic regression models to determine whether age was an independent predictor of SVR. After adjustment for baseline characteristics, age was not significantly associated with the likelihood of achieving SVR either in the entire population or in genotype-specific analyses (Table 3) .
Impact of missing sustained virologic response data
Of the 17 487 patients in the study, 1603 (9%) had missing SVR data. Missing SVR was progressively more prevalent in younger age groups, ranging from 6.9% in patients aged 75 years or older to 13.3% in patients aged below 55 years (Table 1) . We did not find significant differences in predictors of SVR, such as race/ethnicity, age, genotype, cirrhosis, and decompensated cirrhosis, between patients with and those without SVR data (Supplemental Table 2 , Supplemental digital content 2, http://links.lww.com/EJGH/A177). Rates of Table 2 . 
Discussion
Options for the treatment of chronic HCV have improved considerably with the advent of DAA regimens, which have high efficacy and excellent safety profiles. DAAs hold promise in the successful treatment of HCV in clinical subgroups that have traditionally been challenging to treat. Elderly patients represent a significant and rapidly increasing proportion of patients infected with chronic HCV. Our results demonstrate that SOF-based, LDV/SOFbased, and PrOD-based regimens result in high rates of SVR in patients of advanced age. Among difficult-to-treat subgroups, including patients with genotypes 2 and 3, cirrhosis, and decompensated cirrhosis, elderly patients had similar SVRs compared with younger patients. After adjusting for important factors associated with SVR in multivariate models, we found that age was not associated with SVR.
There are few studies examining the association between advanced age and SVR following DAA therapy. Elderly patients are often under-represented in existing clinical trials. In the ION-1, ION-2 , and ION-3 trials, for example, although there was no upper limit of age for inclusion in the study, the number of patients aged 65 or older was too small to compare SVR between younger and older patients [25] [26] [27] . A recent post-hoc pooled analysis of the ION trials and a Japanese trial showed that genotype 1 patients 65 years or older attained SVR rates (98%) equivalent to those of patients younger than 65 years (97%) when treated with LDV/SOF ribavirin [28] , which is consistent with our results. There were only 264 patients aged 65 years or older in these four trials combined and only 24 patients aged 75 years or older. Trials of PrOD for genotype 1 HCV and SOF-based regimens for genotypes 2 and 3 HCV examined age subgroups using cutoffs of 55 or 50 [29] [30] [31] [32] [33] . Therefore, the efficacy of DAAs among patients older than 60 or 65 years cannot be determined from these trials.
The mean age of HCV-infected patients in the USA is expected to continue to increase. As of 2016, patients in the HCV 'baby-boomer' birth cohort born during 1945-1965 were aged 51-71 years. As members of this cohort age, physicians, patients and third-party payers will increasingly be faced with antiviral treatment decisions in elderly patients. The effectiveness of treatment options is an important consideration when making these decisions. Our study shows that DAAs produce high SVRs even in the oldest age cohort (≥75 years) and that advanced age is not an independent negative predictor of SVR. Thus, our results should reassure providers that DAA therapy in older individuals offers similar likelihood of HCV clearance as in younger individuals. Many other factors besides the SVR rate warrant consideration when contemplating HCV treatment in elderly patients, including competing comorbidities, likelihood of progression of liver disease, and long-term benefits of HCV clearance. For example, elderly patients may have comorbidities with greater impact on morbidity and life expectancy than chronic HCV infection. In contrast, elderly patients may also have strong indications for HCV treatment due to the presence of more advanced liver disease. Indeed, our data show that elderly patients are more likely to have cirrhosis or an FIB-4 score of more than 3.25 compared with younger patients (Table 1) , and prior studies suggest that older age is associated with increased risk for complications related to chronic HCV, including accelerated progression to cirrhosis, HCC, and mortality [9] . Therefore, elderly patients may derive substantial benefit from achieving SVR, especially if they lack other serious comorbidities.
The impact of DAA therapy on long-term outcomes requires further investigation and should be considered when making treatment decisions. Our results suggest that antiviral treatment should not, however, be withheld on the basis of age in isolation. This is important to highlight because older age has been shown to be independently associated with a lower likelihood of receiving HCV treatment [8, 9, 20] . Current guidelines do not specify an age limit for consideration of HCV treatment [34] . We agree with continuing this approach and advocate that clinicians carefully consider patients of all age groups for HCV treatment.
An important limitation to our study is that 9% of patients (N =1603) had missing SVR, potentially causing overestimation of SVRs. However, we think bias was unlikely. First, baseline characteristics of patients with and without SVR data were similar, implying that their response to treatment should also be similar. Although more patients without SVR data had early discontinuation, the majority (75%) of patients lacking SVR data completed at least 8 weeks of treatment and had a mean treatment duration of 71 days (Supplemental Table 2 , Supplemental digital content 2, http://links.lww.com/ EJGH/A177). When multiple imputation was used to derive missing SVRs -incorporating both baseline characteristics and duration of treatment -there was little difference between imputed and observed results (Table 4) . Additionally, it was less common for elderly patients to be missing SVR; thus, even if SVR rates were slightly overestimated on account of missing data, they would be less overestimated in older patients than in younger patients. Another limitation is that we did not examine the characteristics of elderly patients with HCV who were not offered treatment in the VA population, and therefore it is possible that the older patients in our study were highly selected.
The strengths of our study include a large sample size of patients aged 60 or older and the use of a national healthcare sample. Our study population also included large numbers of patients in many important clinical subgroups. Although comparing SVRs between each of these subgroups was not the aim of our study, it does allow for some important observations. We have shown, for example, that patients with genotypes 2, 3, and 4 have lower SVR rates compared with genotype 1 patients in all age groups with LDV/SOF-based, SOF-based, and PrODbased regimens. In addition, our study population included a large proportion of patients with alcohol and substance use disorders, as well as patients with psychiatric disease ( Table 1 ), suggesting that patients with these comorbid conditions can be successfully treated with DAAs.
Conclusion
We demonstrate that DAA-based HCV regimens produce high SVRs in patients of advanced age. Clinicians should consider many factors when advising elderly patients on HCV treatment, including comorbid conditions, likelihood of liver disease progression, and potential benefits of HCV eradication. Further research is needed to examine the impact of DAA therapy on long-term HCV-related outcomes especially in elderly patients. Advanced age in and of itself, however, should not be considered a barrier to antiviral treatment.
